ClinicalTrials.gg
Active, not recruitingNCT07265479AdoringUpdated Nov 10, 2026

A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis

A Phase 3 interventional study of Tapinarof cream, 1% and Vehicle Cream in Atopic Dermatitis, sponsored by Organon and Co. Active, not recruiting at 46 sites in 2 countries. Open to participants aged 3 Months to 23 Months. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Organon and Co · Phase 3, Interventional, and Treatment

Updated Nov 10, 2026Now Active, not recruitingNow SuspendedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
187
Allocation
Randomized
Ages
3 Months to 23 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing tapinarof in Dermatitis, Atopic — 1 open to participants now, 2 under way, 1 of them phase 3. tapinarof · Dermatitis, Atopic.

Enrollment
6th of 12
187 · median 168
Started
2025
the only one that year
Phase 3
5 of 12
none open now
Registered
12th of 12
by date
Lead sponsor
5 of 12
Organon and Co

Among the 12 studies testing tapinarof in Dermatitis, Atopic, this one is the 6th largest by enrollment, is the only one that started in 2025, is one of 5 in phase 3, and was the 12th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

1 of the 12 studies testing tapinarof in Dermatitis, Atopic is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

About tapinarof

tapinarof: first FDA approval 2022 (VTAMA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 3 Months to 23 Months · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing tapinarof in Dermatitis, Atopic, or all of them as a file.
02

Study summary

The purpose of this global Phase 3 clinical study is to investigate the safety and efficacy of tapinarof cream, 1% in participants ages 3 months to 23 months (inclusive) with atopic dermatitis.

03

Conditions studied

  • Atopic Dermatitis

Keywords

  • Pediatric Atopic Dermatitis
  • Eczema
  • tapinarof
  • topical
04

Who can participate

Ages eligible
3 Months to 23 Months
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Infants and toddlers born at term (≥37 weeks of gestational age) that are 3 months to \<24 months of age at the Screening visit.
  • Clinical diagnosis of atopic dermatitis (AD), AD covering >5% Body Surface Area (BSA) and validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) score of 2, 3 or 4
  • Legal guardian or primary caregiver is willing and able to sign form before any study-related activities
  • Legal guardian or primary caregiver is able and willing to adhere to protocol requirements

Exclusion criteria

Exclusion Criteria:

  • Significant neurological disorder or history of seizure
  • Know cardiac rhythm or cardiac disorder
  • History of sudden infant death in a sibling
  • Clinically significant chromosome abnormality
  • History of or ongoing serious illness or medical, physical or psychiatric condition(s) that may interfere with the participant's participation
  • Diseases that could cause pruritic and/or sleep disruption
  • Current chronic or acute infection requiring treatment
  • Use of prohibited medication(s) or procedure(s)
  • Use of prohibited medications by breastfeeding mother if breastfeeding participant
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
187 participants (actual)

Study arms

  • Experimental
    Tapinarof cream

    Tapinarof cream, 1%, applied topically once daily

    Drug: Tapinarof cream, 1%

  • Placebo comparator
    Vehicle cream

    Vehicle cream is applied topically once daily for up to 8-weeks.

    Drug: Vehicle Cream

Interventions

  • Tapinarof cream, 1%: Applied topically once daily to lesions on participant's skin during the Double-Blind period. During the Open-Label Period, it will be applied once daily to lesions, as needed.

    Also known as: OG-0505, DMVT-505, GSK2894512A, GSK28994512, STI-1001, WBI-1001

  • DrugVehicle Cream

    Applied topically once daily to lesions on participant's skin during the Double-Blind period.

06

What researchers measure

Primary outcomes

  1. Percentage of participants who have a validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) score of clear or almost clear (0 or 1) and a minimum 2-grade Improvement from Baseline to Week 8

    The vIGA-AD is a global assessment of the current state of the disease. It is a static 5-point scale used to grade overall disease severity (scalp excluded), as determined by the investigator, using the clinical characteristics of erythema, induration/papulation, lichenification, oozing/crusting. The vIGA-AD ranges from 0 to 4 and is reported as Clear (0), Almost clear (1), Mild (2), Moderate (3), and Severe (4). Higher vIGA-AD scores represent more severe disease.

    Time frame: Baseline to last planned visit in the Double-Blind Period, up to 8 weeks.

  2. Percentage of participants who enter with or achieve have a validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) score of clear or almost clear (0 or 1) and a minimum 2-grade Improvement at least once during the Open-Label Period

    The vIGA-AD is a clinical tool for assessing the current state/severity of a subject's atopic dermatitis at a given timepoint.. It is a static 5-point scale used to grade overall disease severity (scalp excluded), as determined by the investigator, using the clinical characteristics of erythema, induration/papulation, lichenification, oozing/crusting. The vIGA-AD ranges from 0 to 4 and is reported as Clear (0), Almost clear (1), Mild (2), Moderate (3), and Severe (4). Higher vIGA-AD scores represent more severe disease.

    Time frame: Baseline to the end of the Open-Label Period, up to 56 weeks.

Secondary outcomes

  1. Percentage of participants with ≥ 75% improvement in Eczema Area and Severity Index (EASI) Score from Baseline to Week 8.

    The EASI is a scoring system that takes into account the overall severity of disease based on lesion severity and the %BSA affected with atopic dermatitis. The EASI is a composite score ranging from 0 -72 that takes into account the degree of erythema, edema/papulation, excoriation, and lichenification (each scored from 0 to 3 separately) for each of four body regions, with adjustment for the %BSA involved for each body region relative to the whole body. The subject's scalp is excluded from this assessment. A higher EASI score represents more severe disease.

    Time frame: Baseline to last planned visit in the Double-Blind Period, up to 8 weeks.

  2. Mean change in percentage of total body surface area (%BSA) affected from Baseline to Week 8

    Assessment of %BSA is an estimate of the percentage of total involved skin with atopic dermatitis. Estimates were made using the handprint method, where the full palmar hand of the participant (fully extended palm, fingers and thumbs together) represented approximately 1% of the total BSA. Body regions are assigned a specific number of handprints with associated percentages (Head and neck = 10% \[10 handprints\], upper extremities = 20% \[20 handprints\], trunk (including axillae and groin) = 30% \[30 handprints\], lower extremities, including buttocks, = 40% \[40 handprints\]). Estimates of the percent involvement of each body region will be multiplied by the fraction of total body area to obtain the total %BSA involved by region and overall.

    Time frame: Baseline to last planned visit in the Double-Blind Period, up to 8 weeks.

  3. Percentage of participants with ≥ 90% improvement in Eczema Area and Severity Index (EASI) score from Baseline to Week 8

    Severity Index (EASI) score from Baseline to Week 8 Description: The EASI is a scoring system that takes into account the overall severity of disease based on lesion severity and the extent of percent body surface area affected with atopic dermatitis. The EASI is a composite score ranging from 0 -72 that takes into account the degree of erythema, edema/papulation, excoriation, and lichenification (each scored from 0 to 3 separately) for each of four body regions, with adjustment for the percent body surface area involved for each body region relative to the whole body. A higher EASI score represents more severe disease.

    Time frame: Baseline to last planned visit in the Double-Blind Period, up to 8 weeks.

  4. Number of participants with one or more Treatment Emergent Adverse Events (TEAEs)

    TEAEs are AEs that started on or after the first dose of study medication.

    Time frame: Baseline to last planned visit in the Double-Blind Period, up to 8 weeks

  5. Number of participants with one or more Treatment Emergent Adverse Events (TEAEs)

    TEAEs are AEs that started on or after the first dose of study medication.

    Time frame: Baseline to the end of the Open-Label Period, up to 56 weeks

  6. Percentage of participants with one or more Treatment Emergent Adverse Events (TEAEs)

    TEAEs are AEs that started on or after the first dose of study medication.

    Time frame: Baseline to last planned visit in the Double-Blind Period, up to 8 weeks .

  7. Percentage of participants with one or more Treatment Emergent Adverse Events (TEAEs)

    TEAEs are AEs that started on or after the first dose of study medication.

    Time frame: Baseline to the end of the Open-Label Period, up to 56 weeks.

  8. Investigator-assessed Local Tolerability Scale (LTS) scores by visit (overall)

    The LTS measures the presence and overall degree of irritation at the application site(s) using a 5-point scale, where 0 indicates no irritation and 4 very severe irritation.

    Time frame: Baseline to last planned visit in the Double-Blind Period, up to 8 weeks

  9. Investigator-assessed Local Tolerability Scale (LTS) scores by visit (overall)

    The LTS measures the presence and overall degree of irritation at the application site(s) using a 5-point scale, where 0 indicates no irritation and 4 very severe irritation.

    Time frame: Beginning of Open-Label to the end of the Open-Label Period, up to 48 weeks.

  10. Investigator-assessed Local Tolerability Scale (LTS) scores by visit (sensitive areas)

    The LTS measures the presence and overall degree of irritation at the application site(s) using a 5-point scale, where 0 indicates no irritation and 4 very severe irritation.

    Time frame: Baseline to last planned visit in the Double-Blind Period, up to 8 weeks

  11. Investigator-assessed Local Tolerability Scale (LTS) scores by visit (sensitive areas)

    The LTS measures the presence and overall degree of irritation at the application site(s) using a 5-point scale, where 0 indicates no irritation and 4 very severe irritation.

    Time frame: Beginning of Open-Label to the end of the Open-Label Period, up to 48 weeks.

07

Study locations

46 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Aug 2027, 20 months after the start.

Of 150 industry-sponsored phase 3 interventional studies under Dermatitis, Atopic, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 28. This study's planned 20 months is above that.

Counting every sponsor, half of 157 studies reached it within 18 months; a quarter within 13 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 21, 2025
First posted
Dec 4, 2025
StartActual
Dec 29, 2025
Primary completionEst.
Aug 2027
CompletionEst.
Aug 2027
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Suspended→Active, not recruiting Reason for stopping removed
changed Oct 5, 2026 · changed Nov 10, 2026
Show all 2 updates
  1. Nov 10, 2026
    Suspended→Active, not recruiting
    Why stopped Reason for stopping removed
  2. Oct 5, 2026
    Active, not recruiting→Suspended
    Why stopped As a precaution, study drug dosing is paused due to a PK finding in OG505-3104. No safety signal or change to the established safety or benefit-risk profile has been identified. The Sponsor is further investigating and assessing the data.

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07265479
Lead sponsor
Organon and Co
Responsible party
Sponsor
First posted
Dec 4, 2025
Start date
Dec 29, 2025
Primary completion
Aug 2027 (estimated)
Completion
Aug 2027 (estimated)
Last update
Nov 10, 2026

Study contacts

Clinical Lead Late-Stage Clinical Development
study director · Organon and Co

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tapinarof

Start the discussion